<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03703999</url>
  </required_header>
  <id_info>
    <org_study_id>4465/AO/18</org_study_id>
    <nct_id>NCT03703999</nct_id>
  </id_info>
  <brief_title>Freestyle Libre Use in Real Life: Efficacy and Acceptance</brief_title>
  <official_title>Efficacy and Acceptance of Freestyle Libre Abbott Use in Real Life in Type 1 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Padova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Padova</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the study is to evaluate efficacy of freestyle Libre system (flash glucose monitoring)&#xD;
      in real life in term of Glycated Haemoglobin reduction and acceptance of the system evaluated&#xD;
      through validated questionnaires after 3 and 6 months of device's use.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Freestyle Libre is a new technology developed to monitor glycemic values in diabetic&#xD;
      patients.&#xD;
&#xD;
      The system is available in Italy from 2014 but in Veneto region reimbursement for insulin&#xD;
      treated diabetic patients is available from august 2017.&#xD;
&#xD;
      International trial (for example Impact trial) demonstrated efficacy of the system (reduction&#xD;
      of the time spent in hypoglycemia).&#xD;
&#xD;
      Aim of this study is to evaluate efficacy in real life in term of glycated haemoglobin&#xD;
      (HbA1c) reduction. The investigators will enrollee in this trial all type 1 diabetic patients&#xD;
      that will start to use the system, on the basis of clinicians decisions and reimbursement&#xD;
      criteria.&#xD;
&#xD;
      Investigators will evaluate changes in HbA1c and changes in hypoglycameia fear and therapy&#xD;
      acceptance through validated questionnaires after 3 and 6 months of system use&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Actual">September 1, 2019</completion_date>
  <primary_completion_date type="Actual">April 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>after 3 and 6 months</time_frame>
    <description>changes in HbA1c values</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in hypoglycemia fear</measure>
    <time_frame>after 3 and 6 months</time_frame>
    <description>Evaluation of hypoglycemia fear through a validated questionnaires, Hypoglycemic Fear Survey (HFS-II). The questionnaires is composed by 33 questions with a Linkert Scale (0-4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in therapy satisfaction</measure>
    <time_frame>after 3 and 6 months</time_frame>
    <description>Evaluation of changes in therapy satisfaction through a validated questionnaires, Diabetes Treatment Satisfaction Questionnaire (DTSQ). The questionnaires is composed by 8 questions with a Linkert Scale (0-6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hypoglycemic episodes</measure>
    <time_frame>after 3 and 6 months</time_frame>
    <description>number of hypoglycemic episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>weight</measure>
    <time_frame>after 3 and 6 months</time_frame>
    <description>changes in weight (Kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin use</measure>
    <time_frame>after 3 and 6 months</time_frame>
    <description>changes in insulin dose (unit/Kg)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>type 1 diabetic patients freestyle Libre</arm_group_label>
    <description>group of type 1 diabetic patients that will be selected to use Freestyle libre on the basis of clinicians decisions and reimbursement criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Type 1 diabetic patients freestyle libre</intervention_name>
    <description>patients selected to use freestyle libre</description>
    <arm_group_label>type 1 diabetic patients freestyle Libre</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        type 1 diabetic patients selected by clinicians to start Freestyle Libre use&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female participants of at least 18 years of age&#xD;
&#xD;
          -  Diagnosis of type 1 diabetes mellitus (diagnosed according to World Health&#xD;
             Organization criteria) for at least 1 year&#xD;
&#xD;
          -  Availability to wear Freestyle Libre sensor&#xD;
&#xD;
          -  Signature of informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy, breastfeeding, intention to undergo pregnancy&#xD;
&#xD;
          -  Known allergies to skin patches or disinfectants used during the study.&#xD;
&#xD;
          -  Skin lesions, irritation, redness, edema in sites where sensors can be applied, as&#xD;
             this might interfere with sensor's placement&#xD;
&#xD;
          -  Use of drugs that may interfere with glucose metabolism (such as steroids) unless they&#xD;
             are chronic therapies whose dosage has remained stable over the past 3 months and is&#xD;
             expected to remain stable during the study period.&#xD;
&#xD;
          -  Severe medical or psychological conditions, which, in the opinion of the medical team,&#xD;
             may compromise patients' safety while using freestyle LIbre sensor&#xD;
&#xD;
          -  Patients enrolled in other clinical trials.&#xD;
&#xD;
          -  patients that usually wear other continuous glucose monitoring system&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 20, 2018</study_first_submitted>
  <study_first_submitted_qc>October 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2018</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Padova</investigator_affiliation>
    <investigator_full_name>Daniela Bruttomesso</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>flash glucose monitoring</keyword>
  <keyword>HbA1c</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

